For­get the IPO, Il­lu­mi­na is near­ing a buy­out of $1.9B liq­uid biop­sy start­up Grail — re­port

Grail, the $1.9 bil­lion, Jeff Be­zos-backed liq­uid biop­sy start­up, may not be go­ing pub­lic af­ter all.

Wednes­day morn­ing, a week af­ter the biotech filed for an IPO, Bloomberg re­port­ed that Il­lu­mi­na was clos­ing in on a deal for the vaunt­ed spin­out. Grail spun out of the se­quenc­ing gi­ant in 2017 and sub­se­quent­ly land­ed just un­der $2 bil­lion from big-name in­vestors on the promise of de­vel­op­ing a blood test to de­tect can­cer far ear­li­er and less in­va­sive­ly than cur­rent­ly pos­si­ble.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER